

ANNUAL MEETING ON WOMEN'S CANCER

2017

NATIONAL HARBOR, MD

MARCH 12 - 15, 2017

2017 Abstracts

As of 12.13.16

Abstracts will be made publically available on the **SGO meeting app** and **website** at the start of the session during which they are presented.

Abstract 1 **Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic *BRCA* mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2**

G.E. Konecny¹, A.M. Oza², A.V. Tinker³, R.L. Coleman⁴, D.M. O'Malley⁵, L. Maloney⁶, K. Wride⁶, L. Rolfe⁶, I. McNeish⁷ and E.M. Swisher⁸

¹University of California, Los Angeles, Los Angeles, CA, USA, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ³British Columbia Cancer Agency, Vancouver, BC, Canada, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁵The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ⁶Clovis Oncology, Inc., Boulder, CO, USA, ⁷Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸University of Washington, Seattle, WA, USA

Abstract 2 **Sentinel lymph node biopsy for early cervical cancer: Results of a randomized prospective, multicenter study (Senticol 2) comparing adding pelvic lymph node dissection vs. sentinel node biopsy only**

P. Mathevet¹, F. Lecuru², L. Magaud³ and F. Bouittie⁴

¹CHU Vaudois, Lausanne, Switzerland, ²Hôpital Européen Georges-Pompidou, Paris, France, ³Hospices Civils de Lyon, Bron, France, ⁴Hospices Civils de Lyon, Pierre-Bénite, France

Abstract 3 **Isolated tumor cells (ITC) identified by sentinel lymph node (SLN) mapping in endometrial cancer: Does adjuvant treatment matter?**

M. Plante¹, J. Stanleigh¹, M.C. Renaud², A. Sebastianelli² and J. Grégoire²

¹Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, ²L'Hotel-Dieu de Quebec, Quebec City, QC, Canada

Abstract 4 **Comparison of long term impact and clinical outcomes of reduced dose vs. standard dose quadrivalent human papillomavirus vaccine in the United States: A database study**

B. Zeybek and A. Rodriguez

The University of Texas Medical Branch, Galveston, TX, USA

- Abstract 5** **Reasons for persistent suboptimal rates of HPV vaccination in the US: Shifting the focus from sexuality to education and awareness**
- A.L. Beavis¹, M. Krakow², K. Levinson¹ and A.F. Rositch³
¹Johns Hopkins Hospital, Baltimore, MD, USA, ²National Cancer Institute, Bethesda, MD, USA, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- Abstract 6** **Hospital readmission as a quality measure in ovarian cancer surgery**
- S. Uppal¹, R. Spencer², M.G. del Carmen³, L.W. Rice² and J. Griggs¹
¹University of Michigan Health Systems, Ann Arbor, MI, USA, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, ³Massachusetts General Hospital/Harvard University, Boston, MA, USA
- Abstract 7** **BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1**
- E.M. Swisher¹, M.I. Harrell¹, K. Lin², R.L. Coleman³, G.E. Konecny⁴, A.V. Tinker⁵, D.M. O'Malley⁶, I. McNeish⁷ and S.H. Kaufmann⁸
¹University of Washington Medical Center, Seattle, WA, USA, ²Clovis Oncology Inc., San Francisco, CA, USA, ³The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁴University of California, Los Angeles, Los Angeles, CA, USA, ⁵British Columbia Cancer Agency, Vancouver, BC, Canada, ⁶The Ohio State University, Columbus Cancer Council, Hilliard, OH, USA, ⁷Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸Mayo Clinic Minnesota, Rochester, MN, USA
- Abstract 8** **Cluster analysis of chemotherapy non-responders for patients with serous epithelial ovarian cancer**
- M.E. McDonald, E.A. Salinas, A.M. Newton, M.J. Goodheart, K.K. Leslie and J. Gonzalez Bosquet
 University of Iowa Hospitals and Clinics, Iowa City, IA, USA
- Abstract 9** **The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis**
- T.B. Turner¹, S.E. Dille¹, H.J. Smith¹, W.K. Huh¹, S.C. Modesitt², S.L. Rose³, L.W. Rice³, J.M. Fowler⁴ and J.M. Straughn Jr.¹
¹University of Alabama at Birmingham, Birmingham, AL, USA, ²University of Virginia Health System, Charlottesville, VA, USA, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, ⁴The Ohio State University, James
- Abstract 10** **Enhanced recovery after surgery (ERAS) for ovarian cancer: Analyzing the cost effectiveness of a recovery program in primary cytoreductive surgery**
- R. Neff¹, J.D. Wright², D.E. Cohn¹ and L.J. Havrilesky³
¹The Ohio State University, Columbus, OH, USA, ²Columbia University College of Physicians and Surgeons, New York, NY, USA, ³Duke University Medical Center, Durham, NC, USA
- Abstract 11** **Activation of the wnt/ β -catenin pathway is associated with an immunosuppressive tumor microenvironment in endometrial cancer**
- K.C. Kurnit, M.F. Munsell, S.S. Xie, J. Bowser and R. Broaddus
 The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Abstract 12** **Immunoediting, neoantigen frequency, and clinical outcome in patients with ovarian clear cell carcinoma**
- K. Hasegawa¹, H. Matsushita², K. Oda³, S. Yamamoto⁴, A. Nishijima³, Y. Imai¹, K. Asada³, Y. Ikeda¹, K. Fujiwara¹, H. Aburatani⁴ and K. Kakimi²
¹Saitama Medical University International Medical Center, Hidaka, Japan, ²The University of Tokyo Hospital, Tokyo, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan

- Abstract 13** **Cervical cancer survivors have high rates of persistent opioid use at 6 months after radiation**
- K. Ward¹, A.A. Ramzan², J. Sheeder², S. Fischer² and C. Lefkowitz²
¹University of Colorado Hospital, Aurora, CO, USA, ²University of Colorado Denver, Denver, CO, USA
- Abstract 14** **Oncologic outcomes of adjuvant chemotherapy in patients with risk factors after radical surgery in FIGO stage IB–IIA cervical cancer**
- K.B. Lee¹, J.M. Lee² and Y.S. Kim¹
¹Gachon University Gil Medical Center, Incheon, South Korea, ²Kyung Hee University East-West Neo Medical Center, Seoul, South Korea
- Abstract 15** **Stage IA-IIA cervical cancer: Disparities in adherence to treatment guidelines and survival in California**
- K.S. Pfaendler¹, J. Chang², A. Ziogas², R.E. Bristow¹ and K.R. Penner³
¹University of California, Irvine Medical Center, Orange, CA, USA, ²University of California, Irvine, Irvine, CA, USA, ³University of California Irvine Medical Center, Orange, CA, USA
- Abstract 16** **Combining whole pelvic radiation with chemotherapy in stage IVB cervical cancer: A novel treatment strategy**
- V.B. Perkins¹, K. Matsuo², S. Mostofizadeh³, T.T. Sims⁴, J.S. Lea⁴, M.J. Carlson⁴, L.D. Roman⁵, B.J. Monk⁶, D.M. Barnes⁷, S. Chen¹, K.N. Moore⁸ and L.L. Holman¹
¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ²Keck School of Medicine of USC, Los Angeles, CA, USA, ³University of Southern California, Los Angeles, CA, USA, ⁴The University of Texas Southwestern Medical Center, Dallas, TX, USA, ⁵LAC+USC Medical Center, Los Angeles, CA, USA, ⁶Arizona Oncology (US Oncology Network), Phoenix, AZ, USA, ⁷University of Arizona Cancer Center at St. Josephs Hospital and Medical Center, Phoenix, AZ, USA, ⁸The University of Oklahoma, Oklahoma City, OK, USA
- Abstract 17** **Combining whole pelvic radiation with chemotherapy in stage IVB cervical cancer: A novel treatment strategy**
- V.B. Perkins¹, K. Matsuo², S. Mostofizadeh³, T.T. Sims⁴, J.S. Lea⁴, M.J. Carlson⁴, L.D. Roman⁵, B.J. Monk⁶, D.M. Barnes⁷, S. Chen¹, K.N. Moore⁸ and L.L. Holman¹
¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ²Keck School of Medicine of USC, Los Angeles, CA, USA, ³University of Southern California, Los Angeles, CA, USA, ⁴The University of Texas Southwestern Medical Center, Dallas, TX, USA, ⁵LAC+USC Medical Center, Los Angeles, CA, USA, ⁶Arizona Oncology (US Oncology Network), Phoenix, AZ, USA, ⁷University of Arizona Cancer Center at St. Josephs Hospital and Medical Center, Phoenix, AZ, USA, ⁸The University of Oklahoma, Oklahoma City, OK, USA
- Abstract 18** **MS7 a transcript-based diagnostic classifier for metastatic disease and worse progression-free survival in endometrioid endometrial cancer patients**
- G.L. Maxwell^{1,2,3}, G. Wang⁴, C. Tian⁴, N.W. Bateman¹, Y. Casablanca^{1,5}, L.J. Havrilesky⁶, M.J. Birrer⁷, C.A. Hamilton¹, T.P. Conrads^{1,3} and K.M. Darcy¹
¹Gynecologic Cancer Center of Excellence, Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Annandale, VA, USA, ²Inova Fairfax Hospital, Falls Church, VA, USA, ³Inova Schar Cancer Institute, Fairfax, VA, USA, ⁴Gynecologic Cancer Center of Excellence, Bethesda, MD, USA, ⁵Wright Patterson Medical Center, Wright Patterson AFB, OH, USA, ⁶Duke University Medical Center, Durham, NC, USA, ⁷Massachusetts General Hospital/Harvard University, Boston, MA, USA
- Abstract 19** **Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma**
- A.M. Montgomery, D.K. Crossman, E.S. Yang, R.D. Alvarez, W.K. Huh, K.S. Bevis, J.M. Straughn Jr., C.A. Leath III and R.C. Arend
University of Alabama at Birmingham, Birmingham, AL, USA

- Abstract 20** **Pretty fly for GPI: Altered carbohydrate metabolism in ovarian cancer**
- R.A. Previs¹, T.J. Moss¹, B. Zand¹, J.M. Hansen¹, R.L. Dood¹, G.N. Armaiz-Pena², Y.A. Lyons¹, R.L. Coleman¹ and A.K. Sood¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Ponce Research Institute, Ponce, Puerto Rico
- Abstract 21** **Uterine transposition**
- R. Ribeiro¹, F.K. Tsumanuma², G.G. Brandalize², R.E. Faria², L. Teles² and J.C. Rebolho¹
¹Hospital Erasto Gaertner, Curitiba, Brazil, ²Hospital Onix, Curitiba, Brazil
- Abstract 22** **Incidence of surgical site infection after implementation of a reduction bundle in gynecologic cancer patients undergoing colon surgery at a comprehensive cancer center**
- M.B. Schiavone¹, L.A. Moukarzel², K. Leong¹, Q. Zhou¹, A. Iasonos¹, K. Long Roche¹, M.M. Leitao¹, D.S. Chi¹, N.R. Abu-Rustum¹ and O. Zivanovic¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²Johns Hopkins School of Medicine, Baltimore, MD, USA
- Abstract 23** **Clinical behavior of low grade serous ovarian carcinoma: An analysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC)**
- T. May, S. Lheureux, M.Q. Bernardini, H. Jiang and A.A. Tone
Princess Margaret Hospital, Toronto, ON, Canada
- Abstract 24** **Patterns of use and outcomes of adjuvant chemotherapy and radiation for early-stage uterine papillary serous carcinoma**
- S. Cham¹, Y. Huang², I. Deutsch¹, J.Y. Hou¹, A.I. Tergas¹, W.M. Burke², D.L. Hershman¹ and J.D. Wright²
¹NYP/Columbia University Medical Center, New York, NY, USA, ²Columbia University College of Physicians and Surgeons, New York, NY, USA
- Abstract 25** **Surgical readmission and survival in women with ovarian cancer: Are short term quality metrics incentivizing decreased long term survival?**
- E.L. Barber, E.C. Rossi and P.A. Gehrig
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Abstract 26** **Knocking out stress: A systems-based identification of optimal drug combinations to improve ovarian cancer outcomes**
- R.L. Dood¹, A.S. Nagaraja¹, Y.A. Lyons¹, J.M. Hansen¹, R.A. Previs¹, D.B. Jackson², R.L. Coleman¹ and A.K. Sood¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Molecular Health GmbH, Heidelberg, Germany
- Abstract 27** **Preoperatively predicting non-home discharge after surgery for gynecologic malignancy**
- C.A. Penn¹, N.S. Kamdar¹, D.M. Morgan¹ and S. Uppal²
¹The University of Michigan Hospitals, Ann Arbor, MI, USA, ²University of Michigan Health Systems, Ann Arbor, MI, USA
- Abstract 28** **A randomized controlled trial comparing the efficacy of perioperative celecoxib versus ketorolac for perioperative pain control**
- M. Ulm¹, C.H. Watson², A.C. ElNaggar¹, T. Tillmanns¹ and L.R. Daily¹
¹University of Tennessee West Cancer Center, Memphis, TN, USA, ²University of Tennessee Health Science Center, Memphis, TN, USA

- Abstract 29** **Liposomal bupivacaine and preoperative acetaminophen: Useful in minimally invasive surgery too?**
- K. Schwirian¹, R.S. Connor², K.J. Kimball³, R.E. Heidel¹, S.K. Adams⁴, S.M. Lenger¹ and L.C. Kilgore³
¹University of Tennessee Graduate School of Medicine, Knoxville, TN, USA, ²Case Western Reserve, MacDonal Women's Hospital, Cleveland, OH, USA, ³University of Tennessee Knoxville, Knoxville, TN, USA, ⁴University Physicians' Association, Knoxville, TN, USA
- Abstract 30** **A cost-utility analysis of sentinel lymph node mapping, selective lymphadenectomy, and routing lymphadenectomy in the management of low-risk endometrial carcinoma**
- R.S. Suidan¹, C.C.L. Sun¹, S.B. Cantor¹, A. Mariani¹, P.T. Soliman¹, S.N. Westin¹, K.H. Lu¹, S.H. Giordano¹ and L.A. Meyer¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Mayo Clinic, Rochester, MN, USA
- Abstract 31** **Overcoming stress effects: A prospective feasibility trial of beta-blockers with upfront ovarian cancer therapy**
- P.H. Thaker¹, L.M. Kuroki^{1,2}, W. Hu³, I. Zigelboim⁴, L.M. Ramondetta³, A.R. Hagemann¹, L.S. Massad¹, M.A. Powell¹, D.G. Mutch¹ and A.K. Sood³
¹Washington University School of Medicine in St. Louis, St. Louis, MO, USA, ²St Louis, MO, USA, ³The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁴St. Luke's Cancer Care Associates, Bethlehem, PA, USA
- Abstract 32** **Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology**
- L.S. Prescott, J.S. Taylor, C.A. Marten, M.F. Munsell, K. Myers, L.A. Meyer, P.T. Ramirez, C.F. Levenback, D.C. Bodurka and K.M. Schmeler
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Abstract 33** **Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer**
- M.A. Geller¹, L.A. Bendzick¹, C. Ryan², S. Chu², A. Lenvik², A.P.N. Skubit¹, K.L.M. Boylan¹, R. Isaksson Vogel¹, J. Miller² and M. Felices²
¹University of Minnesota, Minneapolis, MN, USA, ²University of Minnesota Cancer Center, Minneapolis, MN, USA
- Abstract 34** **Less is more: Macrophage depletion after adaptive resistance improves anti-VEGF therapy**
- Y.A. Lyons, S. Pradeep, J.M. Hansen, R.L. Dood, S. Wu, M.J. Wagner, R.A. Previs, W. Hu, R.L. Coleman and A.K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Abstract 35** **Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy**
- V. La¹, R. Fujikawa², D.M. Janzen², L. Bainvoll², M. Nunez² and S. Memarzadeh²
¹David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, ²University of California, Los Angeles, Los Angeles, CA, USA
- Abstract 36** **Treatment with carboplatin and taxane chemotherapy increases T-cell receptor (TCR) clonality in high-grade serous ovarian cancer (HGSOC)**
- K. LaVigne¹, P. Cybulska¹, T. Walther¹, R.O. Emerson², M. Vignali², K.J. Park¹, D.A. Levine³, D.S. Chi¹, O. Zivanovic¹ and A.E. Snyder Charen¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²Adaptive Biotechnologies, Seattle, WA, USA, ³New York University School of Medicine, New York, NY, USA

- Abstract 37** **Reversal of obesity-driven aggressiveness of endometrial cancer by metformin**
- S.A. Sullivan¹, A.M. Tran¹, L.H. Clark¹, N.W. Bateman², B.L. Hood², T.P. Conrads², D. Lee³, C. Zhou¹, L. Makowski¹ and V.L. Bae-Jump¹
¹University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Gynecologic Cancer Center of Excellence, Annandale, VA, USA, ³Omic Insight, LCC, Durham, NC, USA
- Abstract 38** **Development of an alternative payment model (APM) for endometrial cancer: Opportunities to reduce cost and improve quality**
- J.D. Wright¹, L.J. Havrilesky², D.E. Cohn³, Y. Huang¹, L.W. Rice⁴, C.L. Brown⁵, E.M. Ko⁶ and R.D. Alvarez⁷
¹Columbia University College of Physicians and Surgeons, New York, NY, USA, ²Duke University Medical Center, Durham, NC, USA, ³The Ohio State University, Columbus, OH, USA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, ⁵Memorial Sloan Kettering Cancer Center, New York, NY, USA, ⁶University of Pennsylvania, Philadelphia, PA, USA, ⁷The Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
- Abstract 39** **Utilizing public and commercial payer sources to develop endometrial cancer alternate payment models to bridge provider and payer cost sharing**
- E.M. Ko¹, L.J. Havrilesky², D.E. Cohn³, Y. Huang⁴, R.D. Alvarez⁵, L.W. Rice⁶, C.L. Brown⁷ and J.D. Wright⁴
¹University of Pennsylvania, Philadelphia, PA, USA, ²Duke University Medical Center, Durham, NC, USA, ³The Ohio State University, Columbus, OH, USA, ⁴Columbia University College of Physicians and Surgeons, New York, NY, USA, ⁵University of Alabama at Birmingham, Birmingham, AL, USA, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, ⁷Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Abstract 40** **The effect of a multidisciplinary palliative care initiative on end-of-life care in gynecologic oncology patients**
- M.M. Mullen, L.M. Divine, B. Porcelli, I. Wilkinson-Ryan, M. Dans, L.S. Massad, M.A. Powell, D.G. Mutch, A.R. Hagemann and P.H. Thaker
Washington University School of Medicine in St. Louis, St. Louis, MO, USA
- Abstract 41** **Interim analysis of a phase I/IIA trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients**
- G.L. Maxwell¹, J.C. Elkas², T.P. Conrads¹, K.M. Darcy³, C.A. Hamilton⁴ and G. Peoples⁵
¹Inova Schar Cancer Institute, Fairfax, VA, USA, ²Mid Atlantic Pelvic Surgery Associates, Annandale, VA, USA, ³Uniformed Services University of the Health Sciences, Bethesda, MD, USA, ⁴John P. Murtha Cancer Center, Bethesda, MD, USA, ⁵San Antonio Military Medical Center, Ft Sam Houston, TX, USA
- Abstract 42** **A description of women with the pathogenic variants in the ovarian cancer risk genes *BRIP1*, *RAD51C*, *RAD51D* identified through clinical testing by a hereditary cancer panel**
- L. Usha¹, S. San Roman², H. Gorringer², R. Bernhisel², K. Brown², J. Saam² and S. Manley²
¹Rush University Medical Center, Chicago, IL, USA, ²Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA
- Abstract 43** **Overall survival in *BRCA1* or *RAD51C* methylated vs. mutated ovarian carcinoma following primary treatment with platinum chemotherapy**
- S.S. Bernards, K. Pennington, M.I. Harrell, K.J. Agnew, B.M. Norquist and E.M. Swisher
University of Washington School of Medicine, Seattle, WA, USA
- Abstract 44** **Detection of tumor-derived DNA with combination Pap smear and plasma testing in women with primary ovarian cancer: A potential screening test on the horizon?**
- A. Nickles Fader¹, Y. Wang², N. Papadopoulos³, R.L. Stone¹, T.L. Wang³, E.J. Tanner III¹, I.M. Shih³ and B. Vogelstein²
¹Johns Hopkins Hospital, Baltimore, MD, USA, ²Johns Hopkins University, Baltimore, MD, USA, ³Johns Hopkins School of Medicine, Baltimore, MD, USA

- Abstract 45** **Defining priority symptoms in recurrent ovarian cancer: A comparison of four different criteria from a Gynecologic Oncology Group study (GOG 259)**
- H.S. Donovan¹, L. Wenzel², S. Sereika³, S.E. Ward⁴, R.P. Edwards⁵, R.T. Penson⁶ and T. Hagan⁷
¹University of Pittsburgh, Pittsburgh, PA, USA, ²University of California, Irvine, Irvine, CA, USA, ³University of Pittsburgh School of Nursing, Pittsburgh, PA, USA, ⁴University of Wisconsin, Madison, WI, USA, ⁵Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, ⁶Massachusetts General Hospital/Harvard University, Boston, MA, USA, ⁷Massachusetts General Hospital, Boston, MA, USA
- Abstract 46** **Early palliative care is associated with improved quality of end-of-life care for women with high risk gynecologic malignancies**
- N.S. Nevadunsky¹, C. Zanartu², P. Pinto², R. Barrera², A.R. Van Arsdale¹, Y.S. Kuo¹, B.D. Rapkin¹, A.P. Novetsky¹, G.L. Goldberg¹ and S. Eti²
¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA, ²Montefiore Medical Center, Bronx, NY, USA
- Abstract 47** **Variations in patient preferences over side effects of treatments for ovarian cancer: Baseline results of a randomized controlled clinical trial**
- D.B. Mukamel¹, L. Wenzel², L.J. Havrilesky³, K. Osann², H.A. Ladd⁴, J.L. Walker⁵, A.A. Wright⁶, R.D. Alvarez⁷, R.E. Bristow⁸, P.A. DiSilvestro⁹, R.J. Morgan Jr.¹⁰, J. Lipscomb¹¹ and D.E. Cohn¹²
¹University of California Irvine Medical Center, Orange, CA, USA, ²University of California, Irvine, Irvine, CA, USA, ³Duke University Medical Center, Durham, NC, USA, ⁴UC Irvine Medical Center, Orange, CA, USA, ⁵The University of Oklahoma, Oklahoma City, OK, USA, ⁶Harvard Medical School, Boston, MA, USA, ⁷University of Alabama at Birmingham, Birmingham, AL, USA, ⁸University of California, Irvine Medical Center, Orange, CA, USA, ⁹Women and Infants Hospital, Brown University, Providence, RI, USA, ¹⁰City of Hope, Duarte, CA, USA, ¹¹Emory University School of Medicine, Atlanta, GA, USA, ¹²The Ohio State University, Columbus, OH, USA
- Abstract 48** **Observed toxicities in elderly gynecologic cancer patients treated on phase I clinical trials: The University of Oklahoma Health Sciences Center experience**
- M.E. Buechel¹, A. McGinnis¹, K.S. Wade², S. Vesely³, K.N. Moore³ and C.C. Gunderson¹
¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ²Ochsner Clinic Foundation, New Orleans, LA, USA, ³The University of Oklahoma, Oklahoma City, OK, USA
- Abstract 49** **Endometrial cancer survivors' access to recommended self-care resources to target obesity in a high poverty urban community**
- J.G. Ross¹, V. Escamilla¹, N.K. Lee¹, S.D. Yamada¹ and S.T. Lindau²
¹The University of Chicago Medicine, Chicago, IL, USA, ²University of Chicago, Chicago, IL, USA
- Abstract 50** **Oncological and obstetric outcome of abdominal radical trachelectomy: An updated series of 263 cervical cancer patients from a 12-year experience**
- X. Wu, J. Li and X. Li
 Fudan University Shanghai Cancer Center, Shanghai, China
- Abstract 51** **GOC2: A multicenter prospective trial comparing open, laparoscopic and robotic surgical outcomes in women with endometrial cancer. Part B: Patient-reported outcomes**
- S.E. Ferguson¹, W.H. Gotlieb², L.T. Gien³, C. Giede⁴, V. Samouelian⁵, H. Steed⁶, B. Renkosinski¹, J. Abitbol², T. Warkus⁷, T. Le⁸, V. Martin⁹, T. Panzarella¹, A.L. Covens¹⁰ and M.Q. Bernardini¹
¹Princess Margaret Hospital, Toronto, ON, Canada, ²McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Sunnybrook Odette Cancer Center, Toronto, ON, Canada, ⁴University of Saskatchewan, Saskatchewan, SK, Canada, ⁵Université de Montréal - Hôpital Notre Dame, Montreal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷CHUM Notre Dame Hospital, Montreal, QC, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹Queens University, Kingston, ON, Canada, ¹⁰Sunnybrook Regional Cancer Centre, Toronto, ON, Canada

Abstract 52

Contemporary recurrence and survival outcomes for stage IB squamous cell carcinoma of the vulva: Time to raise the bar

R.L. Stone¹, M. Gornet², J. Berger³, S.A. Sullivan⁴, C.C. Gunderson⁵, J. Acuna⁶, K.K. Zorn⁶, E.J. Tanner III¹, L. Ojalvo² and A. Nickles Fader¹

¹Johns Hopkins Hospital, Baltimore, MD, USA, ²Johns Hopkins School of Medicine, Baltimore, MD, USA, ³Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ⁶University of Arkansas for Medical Sciences, Little Rock, AR, USA

Abstract 53

A phase II, single-dose, open-label study to investigate the safety and efficacy of OTL38 injection for intraoperative imaging of folate receptor-alpha positive ovarian cancer

L.M. Randall¹, R.M. Wenham², P.S. Low³, S.C. Dowdy⁴ and J.L. Tanyi⁵

¹University of California at Irvine Medical Center, Orange, CA, USA, ²H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, ³Purdue University, West Lafayette, IN, USA, ⁴Mayo Clinic, Rochester, MN, USA, ⁵University of Pennsylvania Health System, Philadelphia, PA, USA

Featured Poster Abstracts 54–144

Basic Science

- Abstract 54 NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer
- Abstract 55 Preliminary study of serum microRNAs related with chemoradiotherapy resistance in advanced stage cervical squamous cell carcinoma
- Abstract 56 Mapping HPV integration in precancerous cervical lesions
- Abstract 57 Differential proteomic analysis of metformin response in a preoperative-window clinical trial for endometrial cancer
- Abstract 58 Measurements of adiposity as predictive biomarkers for response to anti-angiogenic treatment in epithelial ovarian cancer: An NRG/GOG ancillary data analysis of GOG 218
- Abstract 59 Relationship of tumor glucocorticoid receptor expression with overall survival in ovarian cancer TCGA data
- Abstract 60 No need to stress: Prospective clinical trial of adrenergic blockade during primary treatment in women with epithelial ovarian cancer
- Abstract 61 Characterization of folate receptor alpha (FR α) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FR α -targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients
- Abstract 62 Obesity-driven metabolic effects differ in ovarian vs. endometrial cancer
- Abstract 63 Using the National Comprehensive Cancer Network guidelines and levels of evidence to prioritize research focus in gynecologic cancer care
- Abstract 64 Human papillomavirus (HPV) type and prevalence in Pacific Islander cervical cancer patients
- Abstract 65 The influence of political party on gynecologic cancer research funding in the United States
- Abstract 66 CCR2 blockade alters the tumor microenvironment immune infiltrate and enhances anti-tumor activity in ovarian cancer
- Abstract 67 Differential expression of immune-related genes in high-grade ovarian serous carcinoma (HGSC): A platform for drug and biomarker discovery
- Abstract 68 One of these things is not like the others: PD-L1 expression in Lynch syndrome associated and sporadic mismatch repair deficient endometrial carcinomas
- Abstract 69 Pharmacologic inhibition of the ataxia telangiectasia mutated and Rad3-related kinase blunts chemotherapy-induced programmed death-1 ligand expression in uterine sarcomas and carcinomas and ovarian carcinomas
- Abstract 70 Novel target for ovarian cancer immunotherapy

Putting the Patient First

- Abstract 71 Rate of ovarian micrometastasis in endometrial cancer: Is ovarian preservation a reasonable option?
- Abstract 72 Fertility-sparing surgery in epithelial ovarian carcinoma: Can we safely push the limits?
- Abstract 73 Reoperation and recurrence rates in women undergoing conservative surgery for low malignant potential tumors
- Abstract 74 Fertility-conserving surgery among young women with stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base

- Abstract 75 Safety of progestational therapy in young women with endometrial cancer
- Abstract 76 Simple vaginal trachelectomy: A valuable fertility preserving option in early-stage cervical cancer
- Abstract 77 Menstrual Pattern after abdominal radical trachelctomy
- Abstract 78 Neoadjuvant chemotherapy followed by vaginal radical trachelectomy to preserve the fertility in young patients with large cervical carcinoma
- Abstract 79 Genome-wide significant associations of common low penetrance single nucleotide polymorphisms with risk of mucinous ovarian carcinoma
- Abstract 80 Decision-making surrounding genetic testing among women with ovarian carcinoma
- Abstract 81 Genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) and the risk of platinum and taxane toxicities: An analysis of GOG 172 and 182
- Abstract 82 Clinicopathologic significance of MMR immunohistochemistry and MLH1 methylation test in women with endometrial cancer
- Abstract 83 Frequency of germline mutations in *BRIP1*, *RAD51C*, and *RAD51D* among women with ovarian, primary peritoneal, and fallopian tube cancer
- Abstract 84 Feasibility of two-antibody vs. four-antibody mismatch repair protein immunohistochemistry as initial screening for Lynch syndrome in patients with endometrial adenocarcinoma
- Abstract 85 Hysterectomy at the time of risk-reducing bilateral salpingo-oophorectomy amongst a cohort of women with BRCA gene mutations
- Abstract 86 Mortality reduction and cost-effectiveness of performing hysterectomy at the time of RRSO for prophylaxis against serous/serous-like uterine cancers in *BRCA1* mutation carriers
- Abstract 87 Prospective patient-elicited value assessments of options in the primary treatment of ovarian cancer
- Abstract 88 Are women with gynecologic malignancies at risk for opioid misuse?
- Abstract 89 Bald and beautiful? Quality of life and chemotherapy-induced alopecia
- Abstract 90 Long-term BMI follow-up after a prospective physical activity intervention for endometrial cancer survivors: What's the skinny?
- Abstract 91 Automated patient-reported symptom data capture, tracking, and intervention during recovery from ambulatory gynecologic cancer surgery: A prospective study
- Abstract 92 Patient and physician expectations and communication regarding ovarian cancer prognosis
- Abstract 93 Weight changes after the diagnosis of endometrial cancer
- Abstract 94 Bridging the gap: A priorities assessment tool to support shared decision making, maximize limited appointment time and increase patient satisfaction
- Abstract 95 The prevalence of sexual dysfunction in ethnically/racially diverse women with gynecologic malignancies
- Surgery**
- Abstract 96 Long term follow-up of women with endometrial cancer, who undergo indocyanine green (ICG) fluorescence-directed sentinel lymph node dissection (SLND)
- Abstract 97 Multicenter study comparing oncologic outcomes in patients with serous and clear cell endometrial carcinoma between two nodal assessment methods: A sentinel lymph node algorithm vs. a comprehensive pelvic and para-aortic lymphadenectomy

- Abstract 98 Multicenter study comparing survival outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm vs. a comprehensive pelvic and paraaortic lymphadenectomy
- Abstract 99 Recurrence in obese patients with stage I endometrioid endometrial cancer: Does para-aortic lymph node dissection matter?
- Abstract 100 Indocyanine green (ICG) fluorescence directed sentinel lymph node dissection (SLND) in women with endometrial cancer
- Abstract 101 Unexpected locations of sentinel lymph nodes in endometrial cancer
- Abstract 102 Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer
- Abstract 103 Sentinel lymph nodes in vulvar cancer: Management dilemmas in patients with positive nodes and larger tumors
- Abstract 104 Survival impact of pelvic and para-aortic lymph node sampling in patients with completely resected stage I-IV uterine serous carcinoma (USC)
- Abstract 105 GOC2: A multi-centre prospective trial comparing open, laparoscopic and robotic surgical outcomes in women with endometrial cancer. Part A: Perioperative outcomes
- Abstract 106 A randomized controlled trial comparing skin closure in obese gynecologic patients: Staples vs. monofilament suture
- Abstract 107 Close vulvar cancer margins are not strongly associated with recurrence or survival
- Abstract 108 A prospective, randomized, open-blinded endpoint (PROBE) trial for safety of oral apixaban vs. subcutaneous enoxaparin for thromboprophylaxis in women with a suspected gynecologic malignancy
- Abstract 109 Supracervical hysterectomy for early-stage endometrial cancer: Does it increase cancer mortality?
- Abstract 110 Delay in time to surgery and survival in patients with type I vs. type II endometrial cancer: A National Cancer Data Base analysis
- Abstract 111 The gynecologic oncology fellowship interview process: Challenges and potential areas for improvement
- Abstract 112 Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer
- Abstract 113 Role of lymphadenectomy and adjuvant treatment in high-risk endometrial cancer with positive lymph nodes: Comparison of a historical series with comprehensive surgical staging and a contemporary series with sentinel lymph nodes
- Abstract 114 Bowel procedures during gynecologic surgery on an enhanced recovery program (ERP): Are perioperative outcomes compromised?
- Abstract 115 Double-barrel wet colostomy is an acceptable alternative to separate bowel and urinary diversions in patients undergoing pelvic exenteration for gynecologic malignancies
- Abstract 116 Accuracy of robotic cytoreduction estimates for ovarian epithelial malignancies
- Abstract 117 Feasibility and safety of same-day discharge after laparoscopic radical hysterectomy for cervical cancer
- Abstract 118 Experiences and attitudes towards gastrointestinal surgery skills training in gynecologic oncology fellowship: A survey of current and former gynecologic oncology fellows

Improving Patient Outcomes

- Abstract 119 Nomogram predicting individual survival following recurrence in advanced stage high-grade ovarian cancer from NRG Oncology/Gynecologic Oncology Group randomized trials of platinum and paclitaxel
- Abstract 120 Prognostic nutritional index independently predicts survival in women with epithelial ovarian carcinoma
- Abstract 121 Ultra-high volume centers result in both reduced 30-day and 90-day risk-adjusted mortality for high-grade serous ovarian cancer
- Abstract 122 Trends in end-of-life care and health care spending in women with uterine cancer
- Abstract 123 Using value-based tools to determine the value of bevacizumab in cervical and ovarian cancer
- Abstract 124 Role of perioperative complications and adjuvant therapy patterns on racial disparity in survival among elderly women with high-grade endometrial cancer
- Abstract 125 The revolving door: Ovarian cancer readmissions in New York State
- Abstract 126 Validating computerized tomography morphometric ratios in relation to clinical and pathological characteristics in endometrial cancer patients
- Abstract 127 Village based screening: A cervical cancer prevention service platform for rural women in Zambia
- Abstract 128 A preoperative algorithm for the management of primary ovarian cancer: A process and outcome evaluation
- Abstract 129 A novel frailty index is associated with sarcopenia and independently predicts survival in advanced ovarian cancer
- Abstract 130 Association of statin use and disease specific survival for women with type II endometrial cancers: Retrospective analysis of a 15-year experience
- Abstract 131 Adjuvant pelvic radiation sandwiched between paclitaxel/carboplatin chemotherapy in women with completely resected uterine serous carcinoma (USC): A prospective phase II trial update
- Abstract 132 Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal cytoreductive surgery
- Abstract 133 Neoadjuvant chemotherapy for in advanced ovarian, fallopian tube and peritoneal cancer: An ancillary study of GOG 262
- Abstract 134 Neoadjuvant chemotherapy vs. primary debulking surgery: A propensity score matched cohort analysis of survival
- Abstract 135 Adjuvant chemotherapy and radiotherapy compared with radiotherapy alone in women with early-stage high-risk endometrial cancer: Analysis of the National Cancer Data Base
- Abstract 136 Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer
- Abstract 137 Comparison of adjuvant therapy for node-positive, high-risk, early-stage cervical cancer: Systemic chemotherapy vs. pelvic irradiation
- Abstract 138 Impact of sociodemographic and tumor characteristics vs. guideline adherent care on stage IIB-IVA cervical cancer survival
- Abstract 139 Minority race is a significant risk factor for treatment by non-gynecologic oncologists in women with pelvic malignancies
- Abstract 140 The cost-effectiveness of cancer care navigation in patients with locoregional cervical cancer undergoing primary chemoradiation

- Abstract 141 Comparison of clinical outcomes in women with advanced ovarian cancer undergoing neoadjuvant chemotherapy who receive three vs. greater than three cycles of chemotherapy after interval cytoreductive surgery
- Abstract 142 Exposure to risk factors for cervical and anal dysplasia in transgender men and women: A retrospective chart review
- Abstract 143 Neoadjuvant chemotherapy for the treatment of stage IV endometrial adenocarcinoma: A retrospective cohort
- Abstract 144 Vaginal brachytherapy and multi-agent chemotherapy increases survival of women with stage I carcinosarcoma

Posters

Abstracts 145–475

Poster 145

The use of novel PP2A activators in combination with PARP inhibitor for the treatment of high-grade serous ovarian cancer

Poster 146

Expression analysis of recurrence and survival-associated genes suggests that there are opportunities for more precise treatment modalities for serous endometrial cancer

Poster 147

Genomic alteration patterns and clinical actionability of comprehensive genomic profiling for the management of endometrial carcinoma

Poster 148

The role of intraperitoneal platinum-based therapy and anti-angiogenic agents in primary ovarian cancer treatment for *BRCA* positive patients

Poster 149

Single-gene prognostic biomarkers in ovarian cancer: Vetting associations by survival-determining clinical confounders

Poster 150

Integrated analysis reveals microRNA mediated immune system regulation in advanced epithelial ovarian cancer associated with clinical prognosis

Poster 151

Vaginal detection of *Porphyromonas somerae* is indicative of endometrial cancer diagnosis

Poster 152

Verteporfin A new chemotherapeutic agent in endometrial cancer

Poster 153

Impact of PARP inhibitor expanded access program on the uptake of genetic testing in newly diagnosed or recurrent ovarian cancer patients in Singapore

Poster 154

Intersection of the DNA repair pathways and immunogenome identifies PDL2 as a prognostic marker in ovarian epithelial cancer

Poster 155

DNA methylation as a predictor of future malignancies in benign or hyperplastic endometrial biopsies

Poster 156

Genetic and therapeutic inhibition of the receptor tyrosine kinase AXL restores paclitaxel chemosensitivity in uterine serous cancer

Poster 157

Dll3 alterations predict poor survival in gynecological cancers

Poster 158

Modulation of CA-125 expression by hTERT in ovarian cancer: Possible implication of PI3K/AKT/mTOR signaling pathway

Poster 159

Impact of ascites volume on clinical outcomes in epithelial ovarian cancer: A cohort study

Poster 160

Serum and tissue miR-21 as a predictor of future malignancy in endometrial hyperplasia without atypia

Poster 161

Clinical and serum predictors of anti-angiogenic toxicity

Poster 162

Clinical challenges associated with universal screening for Lynch syndrome associated endometrial cancer

Poster 163

CTNNB1 predicts better progression-free survival in endometrioid endometrial cancer patients treated with chemotherapy

Poster 164

Investigating variations in the SWI/SNF complex in serous ovarian cancer

Poster 165

A pretreatment mass spectrometry-based serum proteomic test is able to stratify patients with ovarian cancer receiving adjuvant chemotherapy according to overall and progression-free survival and identify patients likely to exhibit chemoresistance

Poster 166

Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities

Poster 167

The predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in determining cervical cancer stage

Poster 168

Evaluation of genomic alterations by next generation sequencing provides a precision medicine-based approach for gynecologic cancers

Poster 169

Evaluation of the impact of comprehensive genomic profiling on clinical outcomes in gynecologic oncology patients

Poster 170

BRCA mutational status to personalize upfront management in high-grade serous advanced ovarian cancer: A multicenter study

Poster 171

A pilot study evaluating biodynamic imaging (BDI) as a novel method in predicting response to chemotherapy in ovarian cancer

Poster 172

Aspirin-PC is a novel, safe and efficacious compound in ovarian cancer

Poster 173

Serum cytokine arrays reveal different cytokine profiles as prognostic factors for overall survival in patients with ovarian high-grade serous and clear cell carcinoma

Poster 174

Novel combination immunotherapy with MUC1 vaccination and immune checkpoint blockade in ovarian cancer

Poster 175

A novel serum alpha fetoprotein cut-point for distinguishing malignant vs. benign ovarian teratoma

Poster 176

Combination of targeted SMAC mimetic SW IV-134 and standard chemotherapy improves cell death and survival in ovarian cancer murine model

Poster 177

Mutations and transcript expression of maternal embryonic leucine zipper kinase in endometrial cancer patients

Poster 178

The differential analysis of serum HE4 levels in epithelial ovarian cancer and other malignant tumors

Poster 179

Variations of gene expression continuously accumulated according to progression of ovarian cancer recurrence

Poster 180

RNA expression patterns in human ascites-derived ovarian cancer cells allow molecular characterization and identification of potential therapeutic targets

Poster 181

Interleukin-6 and leukemia inhibitory factor are expressed in both ovarian cancer tumor cells and stroma and may impact response to anti-estrogen therapy

Poster 182

Uterine leiomyosarcoma: Are novel therapeutics on the horizon?

Poster 183

Characterization of immune regulatory molecules B7-H4 and PD-L1 in low- and high-grade endometrial tumors

Poster 184

Augmenting the MHC II antigen-presentation pathway with epigenetic therapy in epithelial ovarian cancer

Poster 185

Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 therapeutics in ovarian cancer

Poster 186

Use of next generation sequencing to predict response to primary chemotherapy in epithelial ovarian cancer

Poster 187

Prospective assessment of circulating tumor cells (CTCs) in women undergoing surgery for suspected ovarian cancer

Poster 188

Predictors of Lynch syndrome and clinical outcomes among universally screened endometrial cancer patients

Poster 189

Sentinel lymph node biopsy for early cervical cancer: Five years follow-up of a diagnostic, prospective, multicenter study (Senticol 1)

Poster 190

An analysis of efficacy and safety of olaratumab + doxorubicin or doxorubicin alone in patients with uterine leiomyosarcoma: A retrospective assessment of the phase 1b/2 study JGDG

Poster 191

Racial and ethnic outcome differences in the top five women's cancers: A harmonized Surveillance, Epidemiology, and End Results study for diagnoses from 2000-2014

Poster 192

The combination of gonadotropin releasing hormone agonist and levonorgestrel-release intrauterine device/aromatase inhibitor for severe atypical hyperplasia and well-differentiated endometrial carcinoma

Poster 193

The safety and efficacy of bleomycin, etoposide and cisplatin (BEP) chemotherapy in patients with malignant ovarian germ cell tumor

Poster 194

Pseudotyped retroviral replicating vectors for combination prodrug activator gene therapy of ovarian cancer

Poster 195

A multi-institutional analysis of patterns of recurrence and survival with clear cell carcinoma of the ovary

Poster 196

Long-term bevacizumab toxicity in patients with recurrent ovarian cancer

Poster 197

Functional outcomes of laparoscopic-assisted vaginal radical trachelectomy in early-stage cervical cancer: A prospective multicentric cohort of 50 patients

Poster 198

Postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection

Poster 199

Functional outcomes of trachelectomy in early-stage cervical cancer: Vaginal vs. laparoscopic ways

Poster 200

Vocimagene amiretrorepvec (Toca 511) for prodrug activator gene therapy in ovarian cancer models

Poster 201

Focal adhesion kinase (FAK) inhibition overcomes cisplatin-resistance in epithelial ovarian cancer

Poster 202

Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET/CT in advanced epithelial ovarian cancer

Poster 203

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy

Poster 204

Comparison of MRI, PET/CT, and frozen biopsy in the evaluation of lymph node status before fertility-sparing radical trachelectomy in early stage cervical cancer

Poster 205

Continuing neoadjuvant chemotherapy until CA-125 reaches the nadir improves complete cytoreduction by interval debulking surgery in patients with advanced epithelial ovarian cancer

Poster 206

Phase I study combining PARP-inhibition with immune checkpoint blockade in women with *BRCA*-deficient recurrent ovarian cancer

Poster 207

Is sentinel lymph node biopsy safe during radical trachelectomy? A prospective multicenter study

Poster 208

Targeting the ATR-Chk1 axis with PARP inhibition results in tumor regression in *BRCA* mutant models

Poster 209

Measurements of sarcopenia as predictive biomarkers for response to anti-angiogenic treatment in epithelial ovarian cancer: An NRG/GOG ancillary data analysis of GOG 218

Poster 210

Is there a survival benefit associated with intraperitoneal chemotherapy after neoadjuvant chemotherapy for optimally debulked epithelial ovarian cancer patients?

Poster 211

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles in patients with advanced ovarian cancer

Poster 213

Clinical behavior of FIGO stage I endometrioid endometrial adenocarcinoma diagnosed as high-grade on preoperative biopsy and low-grade on hysterectomy specimen

Poster 214

Should ovarian carcinoma metastatic to the inguinal nodes be assigned stage IVB?

Poster 215

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with advanced ovarian cancer

Poster 216

Decreasing levels of BMI1 as a therapeutic approach in endometrial cancer

Poster 217

Placenta-specific protein 1 (PLAC1) expression in serous ovarian cancer is significantly determined by *p53* mutation status

Poster 218

Pathologic response differs between and within tumor sites at the time of interval debulking surgery following neoadjuvant chemotherapy in advanced ovarian cancer

Poster 219

High frequency gene mutations in cervical cancer patients enrolled on a DNA sequencing protocol

Poster 220

Epithelial-mesenchymal transcription factor Snail leads to cancer stem cell phenotype via repression of tumor suppressor miRNA let-7: Snail knockdown restricts metastatic progression in epithelial ovarian carcinomas

Poster 221

Is the immune microenvironment of microsatellite instable endometrial cancer altered in morbidly obese vs. non-obese patients?

Poster 222

Proteogenomic alterations in black endometrioid endometrial cancer patients correlate with poor disease outcome

Poster 223

Trends of treatment for high- and low-grade serous ovarian cancer using the National Cancer Data Base

Poster 224

The use of tumor organoid culture for drug sensitivity testing in endometrial cancer is feasible

Poster 225

Role of positive peritoneal cytology in FIGO stage IB to IIB cervical adenocarcinoma

Poster 226

Genetic variations in vulvar cancer differ from cervical cancer

Poster 227

Repurposing topiramate as a novel targeted therapy for ovarian cancer

Poster 228

Omental disease has a significant impact on overall survival in patients with uterine carcinosarcoma

Poster 229

Characterization of PARP-7 in ovarian cancer cells

Poster 230

Functional characterization of recurrent *FOXA2* mutations in endometrial cancer

Poster 231

Macrometastases in the pelvic lymph nodes as predictors of multiple pelvic and para-aortic node involvement in endometrial cancer

Poster 232

Cisplatin exposure causes metabolic stress and adaptation in ovarian cancer cells

Poster 233

Urinary bisphenol a levels in women with endometrial cancer

Poster 234

A clinical prediction model for chemoresponse in advanced-stage serous ovarian cancer

Poster 235

Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo

Poster 236

Correlation of subcutaneous and visceral fat with outcomes in patients with endometrial malignancies treated with and without bevacizumab

Poster 237

Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme *BRCA*

Poster 238

Differential expression of immune response markers in the endometrium of obese and non-obese women

Poster 239

Exploring the road less traveled: An assessment of outcomes of non-high-grade serous ovarian cancers using the National Cancer Data Base

Poster 240

Collagen prolyl hydroxylases modulate ovarian cancer microenvironment and metastasis

Poster 241

Mast cells are a newly identified immune component of the mesenchymal subtype in high-grade serous ovarian cancer (HGSC)

Poster 242

Fertility-sparing surgery for stage II epithelial ovarian carcinoma: Analysis of oncologic outcomes

Poster 243

Outcomes in early-stage cervical cancer patients with high-risk features on conization followed by low-risk features on radical hysterectomy.

Poster 244

Survival differences of clear cell ovarian and uterine carcinomas

Poster 245

Endometrial cancer cell lines share genomic features with distinct TCGA-identified endometrial carcinoma subtypes

Poster 246

Embryonal rhabdomyosarcoma of the female genital tract

Poster 247

Do patterns of recurrence reveal the most crucial sites of debulking in ovarian cancer?

Poster 248

External validation of chemotherapy response scoring system for histopathologic assessment of tumor regression after neoadjuvant chemotherapy in high-grade serous ovarian cancer

Poster 249

P5RHH-siAXL nanoparticle is a novel targeted therapy in metastatic gynecologic serous cancers

Poster 250

Identification of functional progesterone response elements in the CYP24A1 promoter

Poster 251

Metformin and phenformin inhibit cell proliferation and alter metabolism in high-grade serous ovarian cancer (HGSC)

Poster 252

Key intermediates of the insulin-like growth factor 2 (IGF2) signaling pathway are differentially expressed in high-grade serous carcinoma originating in the fallopian tube as compared to ovary

Poster 253

Centralization of endometrial cancer care: Implications of preoperative subspecialty gynecologic pathology review

Poster 254

Placenta-specific protein 1 (PLAC1) expression regulated by TP53 in gynecologic cancer cell lines

Poster 255

The wnt/ β -catenin-specific inhibitor, ICG-001, proves effective for the treatment of high-grade serous ovarian cancer in murine models through the targeting of cancer initiating cells

Poster 256

Mucinous differentiation is predictive of improved outcomes in low-grade endometrioid carcinoma

Poster 257

Tao brush endometrial cytology vs. office endometrial biopsy: Comparing diagnostic performance in symptomatic women evaluated in the outpatient setting

Poster 258

Marked inter- and intra-patient heterogeneity of T cell infiltrates in primary high-grade serous ovarian cancer

Poster 259

Endometrial cancer patients with a MELF gland pattern treated with hysterectomy only are at an increased risk of lymph node involvement

Poster 260

A single institution's experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions

Poster 261

Septin 2 overexpression promotes serous and clear cell ovarian cancer tumorigenesis

Poster 262

Surrogates of progression-free survival in endometrial cancer patients: An evaluation of necrosis and other measures of tissue composition

Poster 263

Laparoscopic interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer

Poster 264

Ultrasound surveillance of ovarian abnormalities characterized by stable morphology or morphologies changing between cysts, septated cysts, cysts with solid structure or solid structures

Poster 265

Aborted upfront debulking does not reduce likelihood of optimal interval debulking compared with planned neoadjuvant chemotherapy

Poster 266

Mutation profiling of uterine lavage fluid detects early-stage endometrial cancers and discovers a prevalent landscape of driver mutations in women without cancer

Poster 267

Pain persisting after the resolution of ovarian abnormalities

Poster 268

Granulosa cell tumors: A SEER data review of prognostic parameters in 1,815 patients

Poster 269

The DEK oncoprotein functions in ovarian cancer tumorigenesis

Poster 270

Does histologic subtype affect the risk of lymph node metastasis in apparent stage I epithelial ovarian cancer?

Poster 271

Biologically relevant, ovarian cancer-specific targets identified through a functional genomic screen

Poster 272

The impact of tumor fragments in the lumen of fallopian tubes on recurrence and survival in type I and type II endometrial cancers

Poster 273

Nuclear SYK phosphorylation is associated with poor survival in high-grade serous ovarian cancer

Poster 274

Suboptimal primary debulking vs. neoadjuvant chemotherapy followed by interval debulking: Where does the balance tilt?

Poster 275

Gene expression signature based prediction of lymph node metastasis in patients with endometrioid endometrial cancer

Poster 276

Antioxidant gene expression program is deregulated early in serous ovarian cancer

Poster 277

Missing the grade: Correlation of unknown grade with patient demographics, hospital type, and cancer outcomes in epithelial ovarian cancer

Poster 278

Histone deacetylase inhibitor MS-275 potentiates cisplatin toxicity in epithelial ovarian cancer

Poster 279

The impact of ovarian cancer spread on survival in advanced epithelial ovarian cancer: A cohort study

Poster 280

A comparison of tumor size at diagnosis and disease recurrence in type I and type II endometrial carcinoma

Poster 281

The prognostic significance of white adipose tissue inflammation in advanced-stage, high-grade and serous endometrial cancers

Poster 282

Significance of lymph node metastasis on survival of women with uterine adenosarcoma

Poster 283

Correlation between frozen section and final pathology in women with suspected gynecologic malignancies

Poster 284

Asparagus polysaccharide inhibits cell proliferation, adhesion and invasion in endometrial cancer cells

Poster 285

National trends, outcomes and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer

Poster 286

The addition of chemotherapy to adjuvant radiotherapy in patients with intermediate-risk stage IB cervical cancer and the effect on survival

Poster 287

Utility of Adult Comorbidity Evaluation 27 (ACE-27) in predicting survival of stage I endometrial cancer patients

Poster 288

Use of a novel sentinel lymph node mapping algorithm reduces pelvic lymphadenectomy rates in patients with low-grade endometrial cancer

Poster 289

Comparison of outcomes in optimally-cytoreduced ovarian cancer patients receiving postoperative intraperitoneal chemotherapy vs. intravenous dose-dense chemotherapy without bevacizumab

Poster 290

A single institution pilot study for universal Lynch syndrome screening: A key step towards statewide screening and care

Poster 291

A cost comparison of resource utilization before and after implementing an enhanced recovery program (ERP): A significant impact on the 'bottom line'

Poster 292

Trends in the staging of endometrial cancer: An ACS-NSQIP analysis

Poster 293

Comparison of surgical morbidity and time to chemotherapy postoperatively among ovarian cancer patients treated with primary debulking and neoadjuvant chemotherapy

Poster 294

An area for physician intervention: Trends in lifestyle behaviors and cardiovascular risk factors among endometrial cancer patients over a five-year follow-up period

Poster 295

Demographic and geographic factors associated with advanced cervical cancer in a rural state

Poster 296

The high rate of oophorectomy in children with ovarian masses in the United States: What factors are responsible?

Poster 297

Vaginal cancer treatment patterns and its associated disparities

Poster 298

Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery

Poster 299

How old is too old: Safety of minimally invasive gynecologic surgery and early hospital discharge in the oldest elderly

Poster 300

Risk factors for surgical site infection after ovarian cancer debulking: An ACS NSQIP analysis

Poster 301

Is VTE chemoprophylaxis beneficial after robotic hysterectomy with staging for uterine cancer? An analysis of prevalence, prophylaxis and Caprini risk assessment model among 332 patients

Poster 302

Will delaying mammography screening to age 50 worsen breast cancer disparities among African American women?

Poster 303

Thirty-day hospital readmission and mortality in advanced uterine cancer

Poster 304

Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis

Poster 305

Is an enhanced recovery pathway safe and effective in the elderly?

Poster 306

The impact of body mass index (BMI) classification on the likelihood of lymphadenectomy at the time of hysterectomy for endometrial cancer

Poster 307

Didn't you know? Human papillomavirus (HPV) cancer survivors' knowledge and attitudes towards HPV vaccination

Poster 308

Indication for robotic-assisted surgery influences perioperative outcomes and hospital readmissions among women undergoing gynecologic procedures

Poster 309

Stage IB2 cervical cancer: Survival factors associated with treatment modality

Poster 310

A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer patients

Poster 311

Postoperative complication rates after laparoscopic hysterectomy for women with endometrial cancer: Does an overnight stay alter outcomes?

Poster 312

Telemedicine and patient navigation: Effective strategies to deliver regional genetic counseling

Poster 313

Rate and patterns of recurrence in patients undergoing intraperitoneal chemotherapy for advanced epithelial ovarian cancer

Poster 314

Elevated body mass index (BMI) is associated with a decreased risk of recurrence and increased administration of adjuvant radiation and chemotherapy

Poster 315

Surgical outcomes in Jehovah's Witnesses with gynecologic malignancies

Poster 316

Surgery at a high-volume center reduces the impact of income on survival for women with advanced ovarian cancer

Poster 317

Prospective evaluation of a facilitated referral pathway to improve uptake of genetic assessment for women with newly diagnosed ovarian cancer

Poster 318

Minimally invasive staging surgery in women with early-stage endometrial cancer: Analysis of the National Cancer Data Base

Poster 319

Time is money: Does IV Tylenol decrease time to discharge in patients undergoing robotic surgery for endometrial cancer?

Poster 320

Reducing blood transfusion rates in gynecologic oncology patients through application of bundled interventions

Poster 321

Determining risk of postoperative pulmonary embolism in the gynecologic oncology population

Poster 322

Evaluating risk for intensive care unit admission after rapid response team assessment

Poster 323

Is sentinel node mapping in cervical cancer cost effective? Beyond the detection of node metastasis

Poster 324

Reducing patient wait time with computer simulation modeling

Poster 325

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated comprehensive cancer center

Poster 326

A single-institution evaluation of factors affecting wait times from diagnosis to surgery in patients with endometrial cancer

Poster 327

Association between hospital surgical volume and racial disparities in access to care and outcomes for endometrial cancer

Poster 328

Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: A win for patient care

Poster 329

Yield of cytology surveillance after vulvar intraepithelial neoplasia or cancer

Poster 330

Chemotherapy and radiotherapy for the adjuvant treatment of uterine papillary serous carcinoma

Poster 331

Weekly paclitaxel for recurrent ovarian cancer: Does weekly administration during primary therapy impact efficacy and toxicity at recurrence?

Poster 332

A randomized controlled trial of a preoperative patient education program to improve satisfaction and reduce resource utilization

Poster 333

IV and IV/IP chemotherapy as adjuvant treatment in patients with ovarian cancer leads to similar rates of progression free, and overall survival after neoadjuvant chemotherapy

Poster 334

Quantitative and qualitative evaluation of pediatrician attitudes and barriers to HPV vaccination

Poster 335

Pattern of care, health care disparities and their association with survival outcomes in metastatic cervical cancer

Poster 336

Thirty-day hospital readmission and mortality in advanced ovarian cancer

Poster 337

Enrolling patients on gynecologic cancer clinical trials: A single institution experience with a racially diverse urban patient population

Poster 338

Recurrence patterns after minimally invasive surgery for cervical cancer: Outcomes compared to traditional surgery

Poster 339

Patterns of care and outcomes for women with uterine cancer and ovarian metastases

Poster 340

Racial disparities in the utilization of preventive health services among women diagnosed with early-stage endometrial cancer

Poster 341

Risk factors impeding discharge within 24 hours following robotic assisted surgery for gynecologic malignancy in a diverse urban patient population

Poster 342

Adherence to treatment recommendations and outcomes for women with ovarian cancer at time of first recurrence

Poster 343

Opportunistic salpingectomy to decrease the risk of ovarian and tubal cancer during cesarean birth: Frequency, costs and complications--a study of 341 women

Poster 344

Utilization of intraperitoneal chemotherapy for optimally debulked advanced-stage epithelial ovarian cancer: A single institution experience with a racially diverse urban population

Poster 345

Barriers to genetic testing in patients with endometrial carcinoma universally screened for Lynch syndrome

Poster 346

Follow-up study to assess durability of a nursing protocol to improve postpartum inpatient HPV vaccination

Poster 347

Neoadjuvant chemotherapy and cycle number: A national multicenter study

Poster 348

Baseline dyspnea as a predictor of postoperative hospital length of stay in ovarian cancer patients

Poster 349

Efficacy of progestin therapy for endometrial cancer in morbidly obese patients

Poster 350

Initiation of a dysplasia clinic within a division of gynecologic oncology (DGO) at a tertiary cancer center

Poster 351

Using DrugAbacus to determine the value of PD-1 inhibitors in ovarian cancer: How much should they cost?

Poster 352

Change in genetics service model increases ovarian cancer patient referrals and decreases time to consultation: Improving compliance with guideline-based quality care

Poster 353

Negotiating call pay: Money for nothing or your time for free

Poster 354

Identifying factors impacting hospital length of stay and potentially avoidable discharge delays in patients with gynecologic cancer

Poster 355

Testing established endometrial cancer risk prediction models in women presenting with postmenopausal bleeding

Poster 356

Postoperative complications and survivorship trends following ovarian cancer surgery in New York State

Poster 357

Postoperative opioids: Are physicians prescribing more than what is necessary for adequate pain control?

Poster 358

Modified dose-dense paclitaxel monotherapy for recurrent cervical cancer: A possible effective treatment option for salvage therapy

Poster 359

Super-utilization of health care resources among gynecologic oncology patients

Poster 360

Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage endometrioid adenocarcinoma of the uterus

Poster 361

Improving work-life balance: A pilot program of workplace yoga for physician wellness

Poster 362

Chemotherapy costs, but not resource utilization, are inversely correlated with the primary platinum-free interval among outpatients with recurrent ovarian cancer

Poster 363

Hospital readmissions in gynecologic oncology patients: A target for quality improvement

Poster 364

Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival

Poster 365

Association between social integration and cervical cancer screening among women in the United States

Poster 366

Suboptimal treatment of HIV+ women with advanced gynecologic cancer

Poster 367

Racial disparity in the use of neoadjuvant chemotherapy compared with primary debulking surgery in women with ovarian cancer in a racially diverse urban population

Poster 368

Adjuvant therapy for node positive endometrial cancer: Overall survival and disease-free survival improved with combination chemotherapy and radiation for IIIC2 disease

Poster 369

Estimating financial toxicity in patients with gynecological malignancies undergoing chemotherapy

Poster 370

Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of SGO members

Poster 371

Predictors of port site hernia necessitating operative intervention in patients undergoing robotic surgery

Poster 372

In laboratory clinical data we trust? Accuracy and completeness of test requisition form data in a cohort of ovarian and uterine cancer patients referred for clinical genetic testing

Poster 373

Simple low cost intervention decreases missed opportunity visits and increases human papillomavirus (HPV) vaccination in underserved adolescents

Poster 374

The role of imaging in the initial evaluation of cervical cancer

Poster 375

Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients

Poster 376

The trends and factors associated with ovarian preservation in women in the United States: A nationwide study of 469,517 women

Poster 377

Evaluation of major postoperative complications in gynecologic oncology patients undergoing bowel surgery: A quality improvement project

Poster 378

Time to get up and go: Screening to predict postoperative disposition in gynecologic oncology patients

Poster 379

Barriers in the definitive treatment of endometrial cancer

Poster 380

Predictors of unplanned reoperation for ovarian cancer patients from the National Surgical Quality Improvement Program database

Poster 381

Utility of cardiac testing for gynecologic oncology patients receiving pegylated liposomal doxorubicin

Poster 382

Patterns of care for FIGO stage IB-IIA cervical cancer across the United States

Poster 383

Influence of site of care on racial disparities and outcomes for endometrial cancer

Poster 384

Reduction in morbidity after the implementation of minimally invasive surgery for the treatment of patients with endometrial cancer in the US

Poster 385

Comparative study of epithelial ovarian cancer with or without fertility-sparing surgery in Chinese patients

Poster 386

Endometrial cancer in elderly: Does age influence surgical treatment, outcomes and prognosis?

Poster 387

Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with definitive chemoradiation: A meta-analysis

Poster 388

Interval debulking surgery (IDS) vs. primary debulking surgery (PDS) for advanced ovarian cancer treatment: Complete cytoreduction rate and perioperative outcomes

Poster 389

Analysis of clinicopathologic factors predicting disease recurrence in lymph node-negative early-stage endometrial cancer patients who underwent comprehensive surgical staging

Poster 390

Robotic surgery in the management of uterine cancer: An Australian experience

Poster 391

Gynecologic and breast oncology genetic counseling program at a private hospital in Argentina: Our experience

Poster 392

Accuracy of functional and morphological magnetic resonance imaging for pelvic and para-aortic lymph node metastasis in gynecologic cancers

Poster 393

Investigating the impact of interval from primary debulking surgery to initiation of adjuvant chemotherapy in advanced high-grade serous ovarian cancer

Poster 394

HPV vaccination of adolescents in a dedicated refugee clinic

Poster 395

Current awareness and use of bevacizumab in advanced cervical cancer: A survey among US community oncologists

Poster 396

Does conservative treatment represents the best choice in women with adenocarcinoma in situ of the uterine cervix? A single-institutional study

Poster 397

Radiofrequency ablation for the treatment of recurrent gynecological malignancies: A case series

Poster 398

Balloon pneumo-occluder for vaginal distension at the time of high dose rate (HDR) brachytherapy in patients with cervical cancer

Poster 399

Does chemotherapy increase the pelvic toxicity of vaginal brachytherapy for endometrial cancer patients?

Poster 400

The palliative use of cyberknife radiotherapy in gynecologic malignancies: A single institution experience

Poster 401

A comparison between traditional packing and RadiaDyne balloon packing for patients receiving HDR brachytherapy for cervical cancer

Poster 402

Robotic-assisted placement of interstitial brachytherapy with a pelvic mesh sling to reduce gastrointestinal radiation toxicity in patients with gynecologic cancers

Poster 403

Analysis of adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Data Base

Poster 404

Primary radiation as initial management in endometrial cancer

Poster 405

Is this resectable? Validation and refinement of a CT model to predict residual disease and surgical complexity in advanced ovarian cancer

Poster 406

Cardiophrenic lymph nodes in advanced ovarian cancer: A frequent, important and ignored metastatic site

Poster 407

Interventional radiologic therapies for the treatment of ovarian metastases

Poster 408

Enhanced recovery after surgery interactive audit system for gynecologic oncology surgery: Importance of measuring protocol element compliance (you don't know what you don't measure)!

Poster 409

Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer

Poster 410

Impact of consistent intraoperative assessment on predicting tumor size, myometrial invasion, and cervical involvement: Results from an observational cohort

Poster 411

A comparison of robotic laparoendoscopic single site vs. robotic multiport hysterectomy and sentinel lymph node mapping for low grade endometrial cancer: Surgical outcomes and cost analysis

Poster 412

Local cervical recurrence after radical trachelectomy for early-stage cervical cancer: Is completion hysterectomy necessary?

Poster 413

Laparoendoscopic single-site (LESS) surgery for adnexal masses in a gynecologic oncology practice

Poster 414

Trocar site hernia formation in patients undergoing robotically assisted and non-robotically assisted laparoscopic staging surgery for endometrial cancer

Poster 415

Impact of adjuvant chemotherapy in patients with FIGO stage I ovarian clear cell cancer in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013

Poster 416

Utility of indocyanine green (ICG) dye with Firefly fluorescence imaging alone or combined with methylene blue dye for detection of sentinel lymph nodes in endometrial and cervical cancer, and discriminative ability for detecting metastases

Poster 417

Short- and long-term surgical outcomes for single-port risk reducing salpingo-oophorectomy with and without hysterectomy

Poster 418

Achieving adequate colposcopy: Cervical dilation with osmotic dilators prior to laser ablation for treatment of cervical intraepithelial neoplasia

Poster 419

Impact of adjuvant chemotherapy in patients with FIGO stage I endometrioid ovarian carcinoma in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013

Poster 420

Utilizing V-Y fasciocutaneous advancement flaps for vulvar reconstruction

Poster 421

Outcomes of patients with preoperative grade I endometrial cancer and sentinel lymph node mapping

Poster 422

A dual docking robotic technique for surgical staging in high-risk endometrial cancer

Poster 423

Robotic single site radical hysterectomy in early-stage cervical cancer: Preliminary experience

Poster 424

An opportunity to collaborate: An initiative with a university mechanical engineering program to design a new morcellating device

Poster 425

Primary debulking surgery for advanced ovarian cancer: The Kaizen approach to continued improvement in surgical outcomes

Poster 426

Retrospective evaluation of the accuracy of robotic sentinel lymph node detection (RSLND) using indocyanine green (ICG) dye for endometrial and cervical malignancies

Poster 427

Laparoendoscopic single-site (LESS) surgery for endometrial hyperplasia and endometrial cancer

Poster 428

Prognostic impact of surgical nodal assessment in early-stage endometrioid carcinoma of the ovary: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013

Poster 429

Sentinel lymph node mapping using a novel fluorescent modification of the molecular imaging agent tilmanocept

Poster 430

Where does pelvic nerve injury occur during radical hysterectomy for cervical cancer?

Poster 431

Effect of estrogen therapy on ovarian tumor cells treated with cisplatin

Poster 432

Patient, caregiver and physician perceptions of palliative care in ovarian cancer: Insights from the HOPE prospective pilot study

Poster 433

Epidural anesthesia decreases systemic narcotic use without increasing postoperative complications for gynecologic oncology patients undergoing laparotomy

Poster 434

Patient care needs before and after robotic surgery for gynecologic cases in comparison to laparotomy

Poster 435

Obstetric outcomes of patients undergoing abdominal radical trachelectomy for early-stage cervical cancer: The largest series based on 12 years of experience from China

Poster 436

Transrenal ureteral occlusion with alternating coils and sotradecol-soaked gelfoam pledgets in three patients with genitourinary fistulas

Poster 437

Weighing your risks: Obesity and ovarian cancer

Poster 438

Do patients with a history of endometrial hyperplasia or early type I endometrial cancer desire to make aggressive lifestyle changes including bariatric surgery to lose weight and improve health outcomes?

Poster 439

Distance to care is associated with lower health care maintenance and survival in patients with gynecologic malignancies

Poster 440

A digital media diversion improves mood in patients receiving chemotherapy for recurrent gynecologic malignancies: Results of a randomized clinical trial

Poster 441

Inclusion of information regarding sexual side effects during the informed consent process for women undergoing gynecologic cancer surgery: Is it feasible?

Poster 442

A prospective, longitudinal study to identify levels of physical activity in postoperative gynecologic oncology patients

Poster 443

Patient factors associated with completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer

Poster 444

Sexual function following hysterectomy for endometrial cancer: A five-year follow-up investigation

Poster 445

The frequency of self-reported symptoms of lymphedema over five years in patients with uterine carcinoma

Poster 446

Perceptions of risk and reward in *BRCA1* and *BRCA2* mutation carriers choosing salpingectomy for ovarian cancer prevention

Poster 447

Educational intervention to improve code status discussion skills and confidence for obstetrics and gynecology residents

Poster 448

Critical conversations in gynecologic oncology: Pilot study of communication skills training for fellows and advanced practice providers

Poster 449

Comparison of longitudinal patient reported outcomes on an enhanced recovery pathway in patients with ovarian cancer undergoing primary vs. interval cytoreductive surgery

Poster 450

A matter of margins: Surgical-pathologic risk factors for recurrence in extramammary Paget's disease

Poster 451

Prognosis and survival of gynecologic leiomyosarcoma: A National Cancer Data Base study

Poster 452

The significance of lymphovascular space invasion in microinvasive squamous cell carcinoma of the vulva

Poster 453

Surgical staging of borderline ovarian tumors with and without lymphadenectomies: A multi-institutional study

Poster 454

Wnt signaling in human granulosa cell tumors of the ovary

Poster 455

Differential effects of saturated and unsaturated fatty acids on ovarian cancer growth

Poster 456

To screen or not to screen: Occult malignancies associated with extramammary Paget's disease

Poster 457

Can oophorectomy and lymphadenectomy be omitted in patients with endometrial stromal sarcoma (ESS)?

Poster 458

Extramammary Paget's disease of the vulva: Management, recurrence and malignant transformation

Poster 459

Comprehensive genomic profiling of rare gynecological malignancies

Poster 460

What is the reproductive function after conservative surgery for malignant ovarian germ cell tumors? A single institution experience

Poster 461

Cancer in pregnancy: A call for action

Poster 462

Prevalence of lymph node metastasis in clinically apparent early-stage malignant ovarian sex cord-stromal tumors

Poster 463

Depletion of immunosuppressive myeloid-derived suppressor cells impedes ovarian cancer growth

Poster 464

Undifferentiated carcinoma of the ovary: Epidemiology and prognosis of a rare tumor

Poster 465

Role of lymphadenectomy in vulvar melanoma

Poster 466

Optimal surgical and adjuvant treatment modalities in vulvar melanoma: An analysis of 1,780 cases of vulvar melanoma in the National Cancer Data Base

Poster 467

Efficacy of intravaginal 5-fluorouracil as initial treatment for women with high-grade vaginal intraepithelial neoplasia

Poster 468

The significance of preoperative serum cancer antigen 125 in malignant ovarian germ cell tumors

Poster 469

Efficacy of pegylated liposomal doxorubicin in low-grade serous ovarian carcinoma

Poster 470

Declining age of diagnosis in patients with uterine adenocarcinoma (AS): Should ovarian preservation be considered?

Poster 471

Surgical management vs. primary radiotherapy for vulvar cancer

Poster 472

Associations between residual disease and overall survival among histologic subtypes of epithelial ovarian cancer

Poster 473

Impact of adjuvant treatment and prognostic variables in women with uterine carcinosarcoma

Poster 474

Use of granulocyte colony stimulating factors (G-CSFs) with multiagent chemotherapy for gestational trophoblastic neoplasia (GTN)

Poster 475

Fertility-sparing surgery for young patients with sarcoma involving the uterine cervix

Surgical Films

Radical vulvectomy with sentinel node detection using indocyanine green (ICG) and near infrared (NIR) merged visualization

K.A. O'Hanlan

Laparoscopic Institute for Gynecology and Oncology, Portola Valley, CA, USA

Robotic-assisted psoas hitch with ureteral reimplantation

J.J. Mueller and M.M. Leitao

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Uterine artery preserving single-port total laparoscopic radical trachelectomy

S.W. Kim

Yonsei University College of Medicine, Seoul, South Korea

Preoperative algorithm for the management of primary ovarian cancer

V. Broach, R.A. Cowan, N.R. Abu-Rustum, D.S. Chi and O. Zivanovic

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Laparoscopic transperitoneal para-aortic lymphadenectomy: Step by step

R. Ribeiro¹, J.C. Linhares¹, C.L. Minari¹, A.T. Tsunoda¹ and F. Fin²

1Hospital Erasto Gaertner, Curitiba, Brazil, 2Hospital São Vicente, Curitiba, Brazil

Minimally invasive fertility-sparing radical trachelectomy

V. Broach and M.M. Leitao

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Robotic hysterectomy and pelvic lymphadenectomy without Trendelenburg position (BMI 36)

H. Fornalik and N.L. Fornalik

Goshen Center for Cancer Care, Goshen, IN, USA

Radical robotic trachelectomy with uterine artery preservation

G. Guitmann

Brazil, Rio de Janeiro, Rio De Janeiro, Brazil

Extraperitoneal para-aortic laparoscopic lymphadenectomy cytoreduction and posterior retroperitoneal lymphocele drained by laparoscopy

C. Darin, J. Di Guilmi, R.A. Verdura and A.G. Maya

Hospital Britanico de Buenos Aires, Buenos Aires, Argentina

Robotic-assisted excision of large retroperitoneal mass

S. Cham¹, N.A. Goldman² and W.M. Burke³

¹NYP/Columbia University Medical Center, New York, NY, USA, ²The Valley Hospital, Paramus, NJ, USA, ³Columbia University College of Physicians and Surgeons, New York, NY, USA

Fluorescent image guided surgical staging: Pelvic and para-aortic lymphatic system directly visualized with fluorescent image in single-port laparoscopy

I. Lee, Y.S. Chung, Y.J. Lee and S.W. Kim
Yonsei University College of Medicine, Seoul, South Korea

Easy groin reconstruction with random abdominal rotation flap

V. Samouelian¹, T. Warkus² and A. Gagnon³
¹Université de Montréal - Hôpital Notre Dame, Montreal, QC, Canada, ²CHUM Notre Dame Hospital, Montreal, QC, Canada, ³CHUM Notre-Dame Hospital, Montreal, QC, Canada

Laparoscopic cytoreduction of para-aortic lymph nodes

M.E. Giavedoni, J.M. Saadi, D. Odetto and M. Perrotta
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Laparoscopic lymphadenectomy of bulky confluent pelvic and para-aortic nodes in a cervical cancer patient

M.H. Santos¹, M.M.D.A. Sousa¹, G.F. Cintra¹, C.E.M.D.C. Andrade², R. Reis¹ and M.A. Vieira¹
¹Barretos Cancer Hospital, Barretos, Brazil, ²Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, Brazil

Cytoreduction of bulky para-aortic adenopathy from metastatic ovarian cancer

W.Y. Kim and D. Lee
Kangbuk Samsung Hospital, Seoul, South Korea

Laparoscopic para-aortic lymphadenectomy with radical nephrectomy, sigmoidectomy and soft tissue resection of isolated retroperitoneal cervical cancer recurrence

R. Ribeiro¹, R. Kool¹, G. Guilgen², G.G. Brandalize³, J.C. Linhares¹ and A.T. Tsunoda¹
¹Hospital Erasto Gaertner, Curitiba, Brazil, ²Inter-rad, Curitiba, Brazil, ³Hospital Onix, Curitiba, Brazil

ENGOT-OV16/NOVA: Results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer

S. Mahner¹, M.R. Mirza², K.N. Moore³, A.M. Oza⁴, A. Gonzalez⁵, M. Fabbro⁶, S. Banerjee⁷, M. Patel⁸, S. Agarwal⁹ and U.A. Matulonis¹⁰
¹University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ²The Finsen Center, Copenhagen, Denmark, ³The University of Oklahoma, Oklahoma City, OK, USA, ⁴Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ⁵GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Madrid, Spain, ⁶ICM, Institut Régional du Cancer de Montpellier, Montpellier, France, ⁷The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom, ⁸Florida Cancer Specialists Clinical Laboratories, Sarasota, FL, USA, ⁹Tesaro, Inc., Waltham, MA, USA, ¹⁰Dana-Farber Cancer Institute, Boston, MA, USA